Cardiovascular Outcomes According to Urinary Albumin and Kidney Disease in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From the SAVOR-TIMI 53 Trial
暂无分享,去创建一个
Deepak L. Bhatt | E. Braunwald | B. Scirica | Darren K Mcguire | P. Steg | J. Udell | I. Raz | M. Sjöstrand | Ofri Mosenzon | K. Im | Estella Kanevsky | C. Stahre
[1] Michael J Pencina,et al. Net reclassification index at event rate: properties and relationships , 2017, Statistics in medicine.
[2] Deepak L. Bhatt,et al. Prognostic Implications of Biomarker Assessments in Patients With Type 2 Diabetes at High Cardiovascular Risk: A Secondary Analysis of a Randomized Clinical Trial. , 2016, JAMA cardiology.
[3] Deepak L. Bhatt,et al. Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial , 2016, Diabetes Care.
[4] John B Buse,et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. , 2016, The New England journal of medicine.
[5] S. Solomon,et al. Natriuretic Peptide and High-Sensitivity Troponin for Cardiovascular Risk Prediction in Diabetes: The Atherosclerosis Risk in Communities (ARIC) Study , 2016, Diabetes Care.
[6] Deepak L. Bhatt,et al. Troponin and Cardiac Events in Stable Ischemic Heart Disease and Diabetes. , 2015, The New England journal of medicine.
[7] Eric E. Smith,et al. 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). , 2015, Circulation.
[8] M. Woodward,et al. Kidney measures beyond traditional risk factors for cardiovascular prediction: A collaborative meta-analysis , 2015, The lancet. Diabetes & endocrinology.
[9] Olga V. Demler,et al. Tests of calibration and goodness‐of‐fit in the survival setting , 2015, Statistics in medicine.
[10] A. Levey,et al. Glomerular filtration rate and albuminuria for detection and staging of acute and chronic kidney disease in adults: a systematic review. , 2015, JAMA.
[11] Deepak L. Bhatt,et al. Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial , 2014, Diabetes Care.
[12] Deepak L. Bhatt,et al. Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial , 2014, Circulation.
[13] A. Mithal,et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. , 2014, The lancet. Diabetes & endocrinology.
[14] B. Kasiske,et al. Diabetic Kidney Disease– A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO) , 2014, Kidney international.
[15] Deepak L. Bhatt,et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. , 2013, The New England journal of medicine.
[16] Yoshiya Tanaka,et al. Sitagliptin improves albuminuria in patients with type 2 diabetes mellitus , 2013, Journal of Diabetes Investigation.
[17] R. Califf,et al. Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial , 2012, BMJ Open.
[18] M. Woodward,et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis , 2012, The Lancet.
[19] G. Remuzzi,et al. Measurable urinary albumin predicts cardiovascular risk among normoalbuminuric patients with type 2 diabetes. , 2012, Journal of the American Society of Nephrology : JASN.
[20] R. Prager,et al. A comparison of NT-proBNP and albuminuria for predicting cardiac events in patients with diabetes mellitus , 2012, European journal of preventive cardiology.
[21] M. Pencina,et al. Interpreting incremental value of markers added to risk prediction models. , 2012, American journal of epidemiology.
[22] Marcello Tonelli,et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study , 2012, The Lancet.
[23] B. Astor,et al. Combined association of albuminuria and cystatin C-based estimated GFR with mortality, coronary heart disease, and heart failure outcomes: the Atherosclerosis Risk in Communities (ARIC) Study. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[24] Deepak L. Bhatt,et al. The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study. , 2011, American heart journal.
[25] A. Köttgen,et al. High-normal albuminuria and risk of heart failure in the community. , 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[26] Mark Woodward,et al. Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts. , 2011, Kidney international.
[27] Patrick J Heagerty,et al. Temporal trends in the prevalence of diabetic kidney disease in the United States. , 2011, JAMA.
[28] Laura E. Clark,et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. , 2011, Kidney international.
[29] M. Woodward,et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis , 2010, The Lancet.
[30] L. Tavazzi,et al. Prevalence and Prognostic Value of Elevated Urinary Albumin Excretion in Patients With Chronic Heart Failure: Data From the GISSI-Heart Failure Trial , 2010, Circulation. Heart failure.
[31] S. Solomon,et al. Albuminuria in chronic heart failure: prevalence and prognostic importance , 2009, The Lancet.
[32] R. Devereux,et al. N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: a LIFE substudy , 2006, Journal of hypertension.
[33] P. Mehler,et al. Albuminuria as a predictor of heart failure hospitalizations in patients with type 2 diabetes. , 2004, Journal of cardiac failure.
[34] P. Guéret,et al. Development of congestive heart failure in type 2 diabetic patients with microalbuminuria or proteinuria: observations from the DIABHYCAR (type 2 DIABetes, Hypertension, CArdiovascular Events and Ramipril) study. , 2003, Diabetes care.
[35] S. Yusuf,et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. , 2001, JAMA.
[36] F. Harrell,et al. Regression modelling strategies for improved prognostic prediction. , 1984, Statistics in medicine.
[37] Deepak L. Bhatt,et al. Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial. , 2015, Circulation.